Pharmaceutical company Gilead Sciences Inc. said late Friday afternoon it received a federal subpoena tied to a criminal and civil investigation into the making of several company products.
The Foster City, Calif., company said the U.S. Attorney's Office for the Northern District of California asked for documents related to the manufacturing, quality and distribution practices for HIV treatments Atripla, Emtriva, Truvada and Viread; the chronic hepatitis B treatment Hepsera; and the hypertension treatment Letairis.
Gilead said in a brief statement it is cooperating with the investigation.
Company shares fell 2 percent, or 93 cents, to $39.30 in after-hours trading.